These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 20662002)

  • 1. p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma.
    Doyle B; Morton JP; Delaney DW; Ridgway RA; Wilkins JA; Sansom OJ
    J Pathol; 2010 Oct; 222(2):129-37. PubMed ID: 20662002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. You can win by losing: p53 mutations in rhabdomyosarcomas.
    Post SM; Lozano G
    J Pathol; 2010 Oct; 222(2):124-8. PubMed ID: 20821751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer.
    Morton JP; Timpson P; Karim SA; Ridgway RA; Athineos D; Doyle B; Jamieson NB; Oien KA; Lowy AM; Brunton VG; Frame MC; Evans TR; Sansom OJ
    Proc Natl Acad Sci U S A; 2010 Jan; 107(1):246-51. PubMed ID: 20018721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice.
    Nanni P; Nicoletti G; De Giovanni C; Croci S; Astolfi A; Landuzzi L; Di Carlo E; Iezzi M; Musiani P; Lollini PL
    Cancer Res; 2003 Jun; 63(11):2728-32. PubMed ID: 12782574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse Models of Human Gastric Cancer Subtypes With Stomach-Specific CreERT2-Mediated Pathway Alterations.
    Seidlitz T; Chen YT; Uhlemann H; Schölch S; Kochall S; Merker SR; Klimova A; Hennig A; Schweitzer C; Pape K; Baretton GB; Welsch T; Aust DE; Weitz J; Koo BK; Stange DE
    Gastroenterology; 2019 Dec; 157(6):1599-1614.e2. PubMed ID: 31585123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
    Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
    Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras.
    Acin S; Li Z; Mejia O; Roop DR; El-Naggar AK; Caulin C
    J Pathol; 2011 Dec; 225(4):479-89. PubMed ID: 21952947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of mouse models of angiosarcoma driven by p53.
    Salter DM; Griffin M; Muir M; Teo K; Culley J; Smith JR; Gomez-Cuadrado L; Matchett K; Sims AH; Hayward L; Henderson NC; Brunton VG
    Dis Model Mech; 2019 Jul; 12(7):. PubMed ID: 31221668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The p53 tumor suppressor gene and gene product.
    Levine AJ
    Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transgenic mouse model expressing P53(R172H), luciferase, EGFP, and KRAS(G12D) in a single open reading frame for live imaging of tumor.
    Ju HL; Calvisi DF; Moon H; Baek S; Ribback S; Dombrowski F; Cho KJ; Chung SI; Han KH; Ro SW
    Sci Rep; 2015 Jan; 5():8053. PubMed ID: 25623590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.
    Ianzano ML; Croci S; Nicoletti G; Palladini A; Landuzzi L; Grosso V; Ranieri D; Dall'Ora M; Santeramo I; Urbini M; De Giovanni C; Lollini PL; Nanni P
    Oncotarget; 2014 Jan; 5(1):108-19. PubMed ID: 24334679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.
    Westcott PM; Halliwill KD; To MD; Rashid M; Rust AG; Keane TM; Delrosario R; Jen KY; Gurley KE; Kemp CJ; Fredlund E; Quigley DA; Adams DJ; Balmain A
    Nature; 2015 Jan; 517(7535):489-92. PubMed ID: 25363767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma.
    Mohamed AD; Shah N; Hettmer S; Vargesson N; Wackerhage H
    Sci Rep; 2018 Oct; 8(1):15674. PubMed ID: 30353028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer.
    Miller P; Akama-Garren EH; Owen RP; Demetriou C; Carroll TM; Slee E; Al Moussawi K; Ellis M; Goldin R; O'Neill E; Lu X
    Cell Death Differ; 2023 Jul; 30(7):1619-1635. PubMed ID: 37270580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.
    Kasinski AL; Slack FJ
    Cancer Res; 2012 Nov; 72(21):5576-87. PubMed ID: 22964582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma.
    Takahashi Y; Oda Y; Kawaguchi K; Tamiya S; Yamamoto H; Suita S; Tsuneyoshi M
    Mod Pathol; 2004 Jun; 17(6):660-9. PubMed ID: 15098008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo.
    Comiskey DF; Jacob AG; Sanford BL; Montes M; Goodwin AK; Steiner H; Matsa E; Tapia-Santos AS; Bebee TW; Grieves J; La Perle K; Boyaka P; Chandler DS
    Oncogene; 2018 Jan; 37(1):95-106. PubMed ID: 28892044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a novel experimental system using single cell-derived pleomorphic rhabdomyosarcoma cell lines expressing K-RasG12V and deficient in p53.
    Saito H; Suzuki N
    Exp Anim; 2023 Nov; 72(4):446-453. PubMed ID: 37081671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Point mutations of N-ras oncogene and abnormal expression of rasp21, p53 proteins in orbital rhabdomyosarcoma].
    Zhang H; Song G; Zhang S; Chang J; Zhang W; Yu H
    Zhonghua Yan Ke Za Zhi; 2000 Jul; 36(4):267-9, 16. PubMed ID: 11853610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice.
    Jiang D; Dumur CI; Massey HD; Ramakrishnan V; Subler MA; Windle JJ
    PLoS One; 2015; 10(2):e0118029. PubMed ID: 25695772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.